J&J lays out plan to splinter orthopedics business into separate company

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Johnson & Johnson is narrowing its focus again, nearly four years after peeling off its consumer health business.

The health care giant said Tuesday that it will separate its orthopedics business into a standalone company known as DePuy Synthes. The move leaves J&J focused on its pharmaceutical and MedTech segments, which make prescription drugs, contact lenses and technology to treat cardiovascular disease and help with surgeries.

DePuy Synthes is headquartered in Raynham, Massachusetts, but has major operations in Warsaw, Indiana, where pedecessor DePuy Manufacturing was founded in 1895.

The orthopedics business will be led by Namal Nawana, a former CEO of the medical technology business Smith & Nephew, which makes products for sports medicine and wound management and also focuses on orthopedics. London-based Smith & Nephew has operations in Indianapolis, Zionsville and Warsaw.

J&J’s orthopedics business pulled in more than $9 billion in sales last year. But the company said the split will help it focus on higher-growth areas.

The company expects to complete the move over the next 18 to 24 months.

J&J announced in November, 2021, that it would turn its consumer health business, which makes Band-Aids, Listerine and Tylenol into a separate company that later became known as Kenvue.

New Brunswick, New Jersey-based Johnson & Johnson also reported on Tuesday better-than-expected third-quarter earnings and reaffirmed its adjusted earnings guidance for the year.

Company shares slipped more than $2, to $188.74 each, in premarket trading. The shares have already climbed more than 30% so far this year.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In